These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 31670078)

  • 1. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy.
    Ramesh A; Brouillard A; Kumar S; Nandi D; Kulkarni A
    Biomaterials; 2020 Jan; 227():119559. PubMed ID: 31670078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy.
    Ramesh A; Malik V; Ranjani HA; Smith H; Kulkarni AA
    Drug Deliv Transl Res; 2021 Dec; 11(6):2317-2327. PubMed ID: 34365577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF1R- and SHP2-Inhibitor-Loaded Nanoparticles Enhance Cytotoxic Activity and Phagocytosis in Tumor-Associated Macrophages.
    Ramesh A; Kumar S; Nandi D; Kulkarni A
    Adv Mater; 2019 Dec; 31(51):e1904364. PubMed ID: 31659802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supramolecular Nanotherapeutics for Macrophage Immunotherapy.
    Ramesh A; Brouillard A; Kulkarni A
    ACS Appl Bio Mater; 2021 Jun; 4(6):4653-4666. PubMed ID: 35007018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment.
    Wen J; Wang S; Guo R; Liu D
    Eur J Med Chem; 2023 Jan; 245(Pt 1):114884. PubMed ID: 36335744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymersomes-Mediated Delivery of CSF1R Inhibitor to Tumor Associated Macrophages Promotes M2 to M1-Like Macrophage Repolarization.
    Rodriguez-Perdigon M; Jimaja S; Haeni L; Bruns N; Rothen-Rutishauser B; Rüegg C
    Macromol Biosci; 2022 Aug; 22(8):e2200168. PubMed ID: 35624036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supramolecular nanotherapeutics enable metabolic reprogramming of tumor-associated macrophages to inhibit tumor growth.
    Ramesh A; Malik V; Brouillard A; Kulkarni A
    J Biomed Mater Res A; 2022 Aug; 110(8):1448-1459. PubMed ID: 35388955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R.
    Czako B; Marszalek JR; Burke JP; Mandal P; Leonard PG; Cross JB; Mseeh F; Jiang Y; Chang EQ; Suzuki E; Kovacs JJ; Feng N; Gera S; Harris AL; Liu Z; Mullinax RA; Pang J; Parker CA; Spencer ND; Yu SS; Wu Q; Tremblay MR; Mikule K; Wilcoxen K; Heffernan TP; Draetta GF; Jones P
    J Med Chem; 2020 Sep; 63(17):9888-9911. PubMed ID: 32787110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages.
    Zhu M; Bai L; Liu X; Peng S; Xie Y; Bai H; Yu H; Wang X; Yuan P; Ma R; Lin J; Wu L; Huang M; Li Y; Luo Y
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment.
    O'Brien SA; Orf J; Skrzypczynska KM; Tan H; Kim J; DeVoss J; Belmontes B; Egen JG
    Cancer Immunol Immunother; 2021 Aug; 70(8):2401-2410. PubMed ID: 33511454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages.
    Zhang P; Zhao S; Wu C; Li J; Li Z; Wen C; Hu S; An G; Meng H; Zhang X; Yang L
    Immunotherapy; 2018 Aug; 10(11):935-949. PubMed ID: 30149762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
    Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
    Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
    [No Abstract]   [Full Text] [Related]  

  • 13. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
    Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH
    Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy.
    Magkouta SF; Vaitsi PC; Pappas AG; Iliopoulou M; Kosti CN; Psarra K; Kalomenidis IT
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34067348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
    Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
    ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The c.1085A>G Genetic Variant of
    Yeh YM; Hsu SJ; Lin PC; Hsu KF; Wu PY; Su WC; Chang JY; Shen MR
    Clin Cancer Res; 2017 Oct; 23(20):6021-6030. PubMed ID: 28724665
    [No Abstract]   [Full Text] [Related]  

  • 17. Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy.
    Figueiredo P; Lepland A; Scodeller P; Fontana F; Torrieri G; Tiboni M; Shahbazi MA; Casettari L; Kostiainen MA; Hirvonen J; Teesalu T; Santos HA
    Acta Biomater; 2021 Oct; 133():231-243. PubMed ID: 33011297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphoinositide 3-kinase/Akt and its related signaling pathways in the regulation of tumor-associated macrophages polarization.
    Yang D; Yang L; Cai J; Li H; Xing Z; Hou Y
    Mol Cell Biochem; 2022 Oct; 477(10):2469-2480. PubMed ID: 35590082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability.
    Murga-Zamalloa C; Rolland DCM; Polk A; Wolfe A; Dewar H; Chowdhury P; Onder O; Dewar R; Brown NA; Bailey NG; Inamdar K; Lim MS; Elenitoba-Johnson KSJ; Wilcox RA
    Clin Cancer Res; 2020 Feb; 26(3):690-703. PubMed ID: 31636099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomaterials targeting tumor associated macrophages for cancer immunotherapy.
    Zhao C; Pang X; Yang Z; Wang S; Deng H; Chen X
    J Control Release; 2022 Jan; 341():272-284. PubMed ID: 34813877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.